Glioma represents a dominant primary intracranial malignancy in the central nervous
system. Artificial intelligence that mainly includes machine learning, and deep learning …

The development of clinical trials has led to substantial improvements in the prevention and
treatment of many diseases, including brain cancer. Advances in medicine, such as …

The most prevalent and deadly primary malignant glioma in adults is glioblastoma (GBM),
which has a median survival time of about 15 months. Despite the standard of care for …

Increasing evidence suggests that besides mutational and molecular alterations, the
immune component of the tumor microenvironment also substantially impacts tumor …

Background The widespread use of Immune checkpoint-inhibitors (ICI) has revolutionised
treatment of multiple cancer types. However, selecting patients who may benefit from ICI …

While there has been significant progress in AI and neuro-oncologic imaging, clinical utility
remains to be demonstrated. The next wave of progress in this area will be driven by …

Immune checkpoint inhibition (ICI) is effective for replication-repair-deficient, high-grade
gliomas (RRD-HGG). The clinical/biological impact of immune-directed approaches after …

Introduction Gene identification for genetic diseases is critical for the development of new
diagnostic approaches and personalized treatment options. Prioritization of gene translation …

Background The tumor immune microenvironment can influence the prognosis and
treatment response to immunotherapy. We aimed to develop a non-invasive radiomic …

An improved understanding of the cellular and molecular biologic processes responsible for
brain tumor development, growth, and resistance to therapy is fundamental to improving …